Human monoclonal antibody or antigen-binding portion thereof that specifically binds to IGF-IR, pharmaceutical composition comprising the antibody or antigen-binding portion thereof, isolated cell line producing the antibody, isolated nucleic acid molecule, vector, host cell, transgenic animal, method of making of antibody or antigen-binding portion thereof and use of the antibody and the isolated nucleic acid molecule
COHEN BRUCE D.,BEEBE JEAN,MILLER PENELOPE E.,MOYER JAMES D.,CORVALAN JOSE R.,GALLO MICHAEL
申请号：
SK9932003
公开号：
SK287954B6
申请日:
2001.12.20
申请国别(地区):
SK
年份:
2012
代理人:
摘要：
Described is a human monoclonal antibody or antigen-binding portion thereof that specifically binds to insulin-like growth factor I receptor (IGF-IR), wherein said antibody or portion inhibits the binding of IGF-I or IGF-II to IGF-IR and inhibits tumor growth in-vivo； a pharmaceutical composition comprising thereof； an isolated cell line producing the antibody； an isolated nucleic acid molecule, that encodes a heavy chain or an antigen-binding portion thereof or a light chain or an antigen-binding portion thereof of an antibody； a vector comprising the nucleic acid molecule； a host cell； a non-human transgenic animal； a method of making an anti-IGF-IR antibody or antigen-binding portion thereof and use of the antibody.Described is a human monoclonal antibody or antigen-binding portion thereof that specifically binds to insulin-like growth factor I receptor (IGF-IR), wherein said antibody or portion inhibits the binding of IGF-I or IGF-II to IGF-IR and inhibits tumor growth in-vivo； a pharmaceutical composition comprising thereof； an isolated cell line producing the antibody； an isolated nucleic acid molecule, that encodes a heavy chain or an antigen-binding portion thereof or a light chain or an antigen-binding portion thereof of an antibody； a vector comprising the nucleic acid molecule； a host cell； a non-human transgenic animal； a method of making an anti-IGF-IR antibody or antigen-binding portion thereof and use of the antibody.
